STOCK TITAN

[Form 4] Eli Lilly & Co. Insider Trading Activity

Filing Impact
(Moderate)
Filing Sentiment
(Positive)
Form Type
4
Rhea-AI Filing Summary

Ralph Alvarez, a director of Eli Lilly & Co. (LLY), reported an acquisition of company common stock. The Form 4 discloses that on 08/13/2025 he purchased 758 shares at a price of $660.254 per share. After the reported transaction, the filing lists 54,994.58 shares as beneficially owned, held indirectly through a trust. The report includes the standard disclaimer that the reporting person disclaims beneficial ownership except to the extent of pecuniary interest. The form was signed on 08/14/2025 by an authorized filer on behalf of Mr. Alvarez.

Ralph Alvarez, membro del consiglio di amministrazione di Eli Lilly & Co. (LLY), ha segnalato l'acquisto di azioni ordinarie della società. Il Modulo 4 indica che il 13/08/2025 ha acquistato 758 azioni al prezzo di $660.254 ciascuna. Dopo l'operazione segnalata, la comunicazione riporta che risultano 54.994,58 azioni possedute a titolo benefico, detenute indirettamente tramite un trust. Nel rapporto è presente la consueta clausola con cui la persona che segnala rinuncia a rivendicare la proprietà beneficiaria, salvo per l'interesse pecuniario. Il modulo è stato firmato il 14/08/2025 da un delegato autorizzato per conto del sig. Alvarez.

Ralph Alvarez, director de Eli Lilly & Co. (LLY), informó la adquisición de acciones ordinarias de la compañía. El Formulario 4 revela que el 13/08/2025 compró 758 acciones a un precio de $660.254 por acción. Tras la operación informada, la presentación indica que se poseen 54.994,58 acciones en beneficio, mantenidas de forma indirecta a través de un fideicomiso. El informe incluye la cláusula habitual en la que la persona que informa renuncia a declarar la propiedad beneficiaria salvo en la medida de su interés pecuniario. El formulario fue firmado el 14/08/2025 por un presentador autorizado en nombre del Sr. Alvarez.

Eli Lilly & Co.(LLY) 이사인 Ralph Alvarez가 회사 보통주를 취득했다고 보고했습니다. Form 4에는 2025-08-13에 주당 $660.254에 758주를 매수했다고 기재되어 있습니다. 보고된 거래 이후, 제출서류에는 신탁을 통해 간접적으로 보유한 54,994.58주

Ralph Alvarez, administrateur d'Eli Lilly & Co. (LLY), a déclaré l'acquisition d'actions ordinaires de la société. Le Formulaire 4 indique que le 13/08/2025 il a acheté 758 actions au prix de 660,254 $ par action. Après l'opération signalée, le dossier mentionne 54 994,58 actions détenues à titre bénéficiaire, détenues indirectement via une fiducie. Le rapport comprend la clause habituelle précisant que la personne déclarante décline toute propriété bénéficiaire, sauf dans la mesure de son intérêt pécuniaire. Le formulaire a été signé le 14/08/2025 par un déposant autorisé au nom de M. Alvarez.

Ralph Alvarez, ein Direktor von Eli Lilly & Co. (LLY), meldete den Erwerb von Stammaktien des Unternehmens. Aus dem Formular 4 geht hervor, dass er am 13.08.2025 758 Aktien zu einem Preis von $660.254 pro Aktie erwarb. Nach der gemeldeten Transaktion führt die Meldung 54.994,58 Aktien als wirtschaftlich gehalten, indirekt gehalten über einen Trust. Der Bericht enthält den üblichen Haftungsausschluss, dass die meldende Person eine wirtschaftliche Eigentümerschaft mit Ausnahme des geldwerten Interesses bestreitet. Das Formular wurde am 14.08.2025 von einem bevollmächtigten Einreicher im Namen von Mr. Alvarez unterzeichnet.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Director purchased 758 shares at $660.254 and holds ~54,994.58 shares indirectly via a trust.

The transaction is a routine insider purchase by a director, disclosed on a Form 4. The purchase price of $660.254 per share and the relatively small increment of 758 shares suggest a non‑material open‑market buy by a director rather than a large, strategic block acquisition. Beneficial ownership is reported as indirect via a trust, which affects control and voting considerations; the filing includes the standard pecuniary interest disclaimer. There are no derivative transactions or exercises disclosed.

TL;DR: Governance disclosure is complete for this single non‑derivative purchase; ownership is indirect through a trust.

The Form 4 properly identifies the reporting person as a director and indicates the filing is by one reporting person. The record shows an acquired amount, acquisition code "P" (purchase), and the ownership form marked as indirect with a nature of indirect ownership described as "By Trust." The standard ownership disclaimer is included. No indications of option exercises, dispositions, or plan-based trading are present in this filing.

Ralph Alvarez, membro del consiglio di amministrazione di Eli Lilly & Co. (LLY), ha segnalato l'acquisto di azioni ordinarie della società. Il Modulo 4 indica che il 13/08/2025 ha acquistato 758 azioni al prezzo di $660.254 ciascuna. Dopo l'operazione segnalata, la comunicazione riporta che risultano 54.994,58 azioni possedute a titolo benefico, detenute indirettamente tramite un trust. Nel rapporto è presente la consueta clausola con cui la persona che segnala rinuncia a rivendicare la proprietà beneficiaria, salvo per l'interesse pecuniario. Il modulo è stato firmato il 14/08/2025 da un delegato autorizzato per conto del sig. Alvarez.

Ralph Alvarez, director de Eli Lilly & Co. (LLY), informó la adquisición de acciones ordinarias de la compañía. El Formulario 4 revela que el 13/08/2025 compró 758 acciones a un precio de $660.254 por acción. Tras la operación informada, la presentación indica que se poseen 54.994,58 acciones en beneficio, mantenidas de forma indirecta a través de un fideicomiso. El informe incluye la cláusula habitual en la que la persona que informa renuncia a declarar la propiedad beneficiaria salvo en la medida de su interés pecuniario. El formulario fue firmado el 14/08/2025 por un presentador autorizado en nombre del Sr. Alvarez.

Eli Lilly & Co.(LLY) 이사인 Ralph Alvarez가 회사 보통주를 취득했다고 보고했습니다. Form 4에는 2025-08-13에 주당 $660.254에 758주를 매수했다고 기재되어 있습니다. 보고된 거래 이후, 제출서류에는 신탁을 통해 간접적으로 보유한 54,994.58주

Ralph Alvarez, administrateur d'Eli Lilly & Co. (LLY), a déclaré l'acquisition d'actions ordinaires de la société. Le Formulaire 4 indique que le 13/08/2025 il a acheté 758 actions au prix de 660,254 $ par action. Après l'opération signalée, le dossier mentionne 54 994,58 actions détenues à titre bénéficiaire, détenues indirectement via une fiducie. Le rapport comprend la clause habituelle précisant que la personne déclarante décline toute propriété bénéficiaire, sauf dans la mesure de son intérêt pécuniaire. Le formulaire a été signé le 14/08/2025 par un déposant autorisé au nom de M. Alvarez.

Ralph Alvarez, ein Direktor von Eli Lilly & Co. (LLY), meldete den Erwerb von Stammaktien des Unternehmens. Aus dem Formular 4 geht hervor, dass er am 13.08.2025 758 Aktien zu einem Preis von $660.254 pro Aktie erwarb. Nach der gemeldeten Transaktion führt die Meldung 54.994,58 Aktien als wirtschaftlich gehalten, indirekt gehalten über einen Trust. Der Bericht enthält den üblichen Haftungsausschluss, dass die meldende Person eine wirtschaftliche Eigentümerschaft mit Ausnahme des geldwerten Interesses bestreitet. Das Formular wurde am 14.08.2025 von einem bevollmächtigten Einreicher im Namen von Mr. Alvarez unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Alvarez Ralph

(Last) (First) (Middle)
LILLY CORPORATE CENTER

(Street)
INDIANAPOLIS IN 46285

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ELI LILLY & Co [ LLY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/13/2025 P 758 A $660.254 758 I By Trust(1)
Common Stock 54,994.58 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of the Reporting Person's pecuniary interest therein, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Remarks:
/s/ Jonathan Groff for Ralph Alvarez, pursuant to authorization on file 08/14/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Lilly Eli & Co

NYSE:LLY

LLY Rankings

LLY Latest News

LLY Latest SEC Filings

LLY Stock Data

592.10B
944.35M
0.16%
84.16%
0.85%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
INDIANAPOLIS